GameStop Corp. filed its quarterly report on Form 10-Q with the SEC on September 9, 2026, covering the fiscal quarter ended August 1, 2026, and disclosing net income of $298.7 million for the period alongside a significant equity investment and derivative activity.
Korn Ferry filed a current report on September 9, 2026, to recast historical segment information from its Annual Report for the fiscal year ended April 30, 2026, reflecting a reorganization of its reportable business segments along geographic lines effective May 1, 2026.
Jersey Mike's Subs Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on September 9, 2026, covering the quarterly period ended June 28, 2026, its first quarterly report since incorporation.
Sunbelt Rentals Holdings, Inc. filed its quarterly report on Form 10-Q with the SEC on September 9, 2026, covering the fiscal first quarter ended July 31, 2026.
Korn Ferry filed its Form 10-Q with the U.S. Securities and Exchange Commission on September 9, 2026, covering the quarterly period ended July 31, 2026, and reporting fee revenue and net income results for the first fiscal quarter of 2027.
Intuit Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission on September 9, 2026, covering the fiscal year ended July 31, 2026, under Commission File Number 0-21180.
Urban Outfitters, Inc. filed its quarterly report on Form 10-Q with the SEC on September 9, 2026, covering the three- and six-month periods ended July 31, 2026.
Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), filed a Form 4 on September 9, 2026, disclosing the sale of common stock on September 4, 2026, pursuant to two separate Rule 10b5-1 trading plans.
Seshadri Neervannan, Chief Operating Officer of Tarsus Pharmaceuticals, Inc., filed a Form 4 on September 9, 2026, reporting the sale of 4,564 shares of common stock on September 4, 2026, executed under a pre-established Rule 10b5-1 trading plan.
Bobak R. Azamian, President, CEO, and Board Chair of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), filed a Form 4 on September 9, 2026, reporting the sale of 10,000 shares of common stock on September 4, 2026, executed under a pre-established Rule 10b5-1 trading plan.